LPA receptor 1 (LPAR1) is a novel interaction partner of Filamin A that promotes Filamin A phosphorylation, MRTF-A transcriptional activity and oncogene-induced senescence.

Autor: Konopa A; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Meier MA; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Franz MJ; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Bernardinelli E; Institute of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria., Voegele AL; Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Atreya R; Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Ribback S; Institute of Pathology, University of Greifswald, Greifswald, Germany., Roessler S; Institute of Pathology, University of Heidelberg, Heidelberg, Germany., Aigner A; Rudolf Boehm Institute of Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig, Leipzig, Germany., Singer K; Department for Pathology, University Hospital Tuebingen, 72076, Tuebingen, Germany., Singer S; Department for Pathology, University Hospital Tuebingen, 72076, Tuebingen, Germany., Sarikas A; Institute of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria., Muehlich S; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. susanne.muehlich@fau.de.

Publikováno v: Oncogenesis [Oncogenesis] 2022 Dec 28; Vol. 11 (1), pp. 69. Date of Electronic Publication: 2022 Dec 28.

ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2.

Autor: Huebner K; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Erlenbach-Wuensch K; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany., Prochazka J; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Sheraj I; Department of Biological Sciences, Middle East Technical University, 06800, Ankara, Turkey., Hampel C; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Mrazkova B; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Michalcikova T; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Tureckova J; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Iatsiuk V; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Weissmann A; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Ferrazzi F; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.; Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, 91054, Erlangen, Germany., Kunze P; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Nalli E; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Sammer E; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Gehring A; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Cheema MM; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany., Paap EM; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Soederberg A; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Fischer C; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Paul S; Department of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Jodhpur, 342037, India., Mahadevan V; Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, 560100, India., Ndreshkjana B; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany., Meier MA; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich Alexander University Erlangen-Nürnberg, 91058, Erlangen, Germany., Muehlich S; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich Alexander University Erlangen-Nürnberg, 91058, Erlangen, Germany., Geppert CI; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany., Merkel S; Department of Surgery, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany., Grutzmann R; Department of Surgery, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany., Roehe A; Department of Pathology and Legal Medicine, Federal University of Health Sciences of Porto Alegre, Porto Alegre, 90050-170, Brazil., Banerjee S; Department of Biological Sciences, Middle East Technical University, 06800, Ankara, Turkey., Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany., Sedlacek R; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic., Schneider-Stock R; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany. regine.schneider-stock@uk-erlangen.de.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany. regine.schneider-stock@uk-erlangen.de.

Publikováno v: Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2022 Jul 15; Vol. 79 (8), pp. 423. Date of Electronic Publication: 2022 Jul 15.

Detection of Cellular Senescence in Human Primary Melanocytes and Malignant Melanoma Cells In Vitro.

Autor: Zimmermann T; Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany., Pommer M; Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany., Kluge V; Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany., Chiheb C; Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany., Muehlich S; Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany., Bosserhoff AK; Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91052 Erlangen, Germany.; Comprehensive Cancer Center (CCC) Erlangen-EMN, 91054 Erlangen, Germany.

Publikováno v: Cells [Cells] 2022 Apr 28; Vol. 11 (9). Date of Electronic Publication: 2022 Apr 28.

Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence.

Autor: Schreyer L; Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany., Mittermeier C; Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore., Franz MJ; Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany., Meier MA; Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany., Martin DE; Gene Center, Department of Chemistry and Pharmacy, Ludwig-Maximilians-University Munich, 81377 Munich, Germany., Maier KC; Gene Center, Department of Chemistry and Pharmacy, Ludwig-Maximilians-University Munich, 81377 Munich, Germany., Huebner K; Experimental Tumor Pathology, Institute of Pathology, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany., Schneider-Stock R; Experimental Tumor Pathology, Institute of Pathology, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany., Singer S; Department for Pathology, University Hospital Tuebingen, 72076 Tuebingen, Germany., Holzer K; Department for Pathology, University Hospital Tuebingen, 72076 Tuebingen, Germany., Fischer D; Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany., Ribback S; Institute for Pathology, University of Greifswald, 17475 Greifswald, Germany., Liebl B; LGL Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, 85764 Oberschleißheim, Germany., Gudermann T; Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-University Munich, 80336 Munich, Germany., Aigner A; Rudolf Boehm Institute of Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig, 04107 Leipzig, Germany., Muehlich S; Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2021 Oct 26; Vol. 13 (21). Date of Electronic Publication: 2021 Oct 26.

Expression Profiling Identified TRPM7 and HER2 as Potential Targets for the Combined Treatment of Cancer Cells.

Autor: Egawa, Miyuki¹ (AUTHOR) miyuki.egawa@campus.lmu.de, Schmücker, Eva¹ (AUTHOR) eva_schmuecker@gmx.de, Grimm, Christian^1,2 (AUTHOR) christian.grimm@med.uni-muenchen.de, Gudermann, Thomas^1,3 (AUTHOR) thomas.gudermann@lrz.uni-muenchen.de, Chubanov, Vladimir¹ (AUTHOR) thomas.gudermann@lrz.uni-muenchen.de

Publikováno v: Cells (2073-4409). Nov2024, Vol. 13 Issue 21, p1801. 20p.